{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:35:21Z","timestamp":1792460121103,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ymgme.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:04:50Z","timestamp":1522454690000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"title":["Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)"],"prefix":"10.1016","volume":"124","author":[{"given":"Janet","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-6457","authenticated-orcid":false,"given":"Jerry","family":"Vockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Zori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dimmock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-3112","authenticated-orcid":false,"given":"Cary O.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Bilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoling H.","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Olbertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Merilainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3743-8044","authenticated-orcid":false,"given":"Kevin","family":"Larimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.03.006_bb0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"For the American College of Medical Genetics Genomics Therapeutics Committee. Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-010-9253-9","article-title":"High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial","volume":"34","author":"ten Hoedt","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/87565641.2016.1243109","article-title":"Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria","volume":"41","author":"Bilder","year":"2016","journal-title":"Dev. Neuropsychol."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2018.03.006_bb0020","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1007\/s10545-008-0978-7","article-title":"Quality of life in noncompliant adults with phenylketonuria after resumption of the diet","volume":"31","author":"Bik-Multanowski","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0025","series-title":"Novato","author":"Kuvan [package insert]","year":"2016"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10545-010-9073-y","article-title":"The reality of dietary compliance in the management of phenylketonuria","volume":"33","author":"MacDonald","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(02)09334-0","article-title":"How practical are recommendations for dietary control in phenylketonuria?","volume":"360","author":"Walter","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0040","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/A:1020158631102","article-title":"Phenylketonuria in adulthood: a collaborative study","volume":"25","author":"Koch","year":"2002","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0050","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/gim.2013.10","article-title":"Newborn screening 50\u202fyears later: access issues faced by adults with PKU","volume":"15","author":"Berry","year":"2013","journal-title":"Genet. Med."},{"issue":"suppl","key":"10.1016\/j.ymgme.2018.03.006_bb0065","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ymgme.2011.08.005","article-title":"Follow up of phenylketonuria patients","volume":"104","author":"Demirkol","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0070","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","article-title":"Adherence to clinic recommendations among patients with phenylketonuria in the United States","volume":"120","author":"Jurecki","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgmr.2015.12.004","article-title":"Phenylketonuria (PKU): a problem solved?","volume":"6","author":"Brown","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0080","first-page":"1007","article-title":"New strategies for the treatment of phenylketonuria (PKU)","volume":"4","author":"Strisciuglio","year":"2014","journal-title":"Meta"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173269","article-title":"Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria","volume":"12","author":"Bell","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0095","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1073\/pnas.96.5.2339","article-title":"A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase","volume":"96","author":"Sarkissian","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0100","series-title":"Evaluation of Multiple Dosing Regimens In Phase 2 Studies of \u201crAvPAL-PEG\u201d for Control of Blood Phenylalanine Levels in Adults With Phenylketonuria","author":"Thomas","year":"2015"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0105","series-title":"Phase 2 Long-term Pegvaliase Treatment for Adults with Phenylketonuria: Updated Year 5 Safety and Efficacy Data from the PAL-003 Extension","author":"Zori","year":"2017"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0110","series-title":"Evaluation of an Induction, Titration, and Maintenance Dosing Regimen in a Phase 2 Study of \u201crAvPAL-PEG\u201d for Control of Blood Phenylalanine Levels in Adults With Phenylketnouria (PKU)","author":"Zori","year":"2015"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.03.003","article-title":"Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation Phase 3 clinical trial","author":"Harding","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409816669373","article-title":"An adaptation of the profile of mood states for use in adults with phenylketonuria","volume":"4","author":"Bacci","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jval.2015.01.008","article-title":"Evaluation of neuropsychiatric function in phenylketonuria: psychometric properties of the ADHD rating scale-IV and adult ADHD self-report scale inattention subscale in phenylketonuria","volume":"18","author":"Wyrwich","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409816639316","article-title":"Content validity of the ADHD rating scale (ADHD RS-IV) and adult ADHD self-report scale (ASRS) in phenylketonuria","volume":"4","author":"Wyrwich","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ymgme.2014.11.011","article-title":"A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria","volume":"114","author":"Burton","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0140","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). Version 18.0. https:\/\/www.meddra.org\/. Accessed December 13, 2017."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0145","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0150","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0155","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03","author":"National Cancer Institute, National Institutes of Health, Department of health and human services","year":"2010"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1037\/neu0000337","article-title":"Cognitive outcomes in early-treated adults with phenylketonuria (PKU): a comprehensive picture across domains","volume":"31","author":"Palermo","year":"2017","journal-title":"Neuropsychology"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0165","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1037\/neu0000336","article-title":"The impact of phenylalanine levels on cognitive outcomes in adults with phenylketonuria: effects across tasks and developmental stages","volume":"31","author":"Romani","year":"2017","journal-title":"Neuropsychology"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0294-x","article-title":"Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries","volume":"10","author":"Bosch","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0175","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1158\/2326-6066.CIR-14-0029","article-title":"Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses","volume":"2","author":"Eisen","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymgme.2018.03.006_bb0195","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymgme.2018.03.006_bb0200","series-title":"Strategies for Successful Long-Term Engagement of Adults With Phenylalanine Hydroxylase Deficiency Returning to the Clinic Journal of Inborn Errors of Metabolism and Screening","first-page":"1","volume":"5","author":"Thomas","year":"2017"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218300210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218300210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T13:59:03Z","timestamp":1582552743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218300210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1096719218300210"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.03.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}